Table 2.
Qualitative evolution of QFT-P and HBHA IFN-γ levels during treatment.
| Positivity rate at each timepoint | HBHA | TB1 only | TB2 only | QFT-P (TB1 and/or TB2) |
|---|---|---|---|---|
| T0 | 31.1% (41/132) | 4.5% (6/132) | 34.8% (46/132) | 52.3% (69/132) |
| T1 | 56.1% (74/132) | 2.3% (3/132) | 42.4% (56/132) | 50.8% (67/132) |
| T2 | 67.4% (89/132) | 2.3% (3/132) | 43.9% (58/132) | 55.3% (73/132) |
| Trend between T0 and T1 | ||||
| Increase | 66.7% (88/132) | 56.1% (74/132) | 47.7% (63/132) | – |
| Decrease | 24.2% (32/132) | 41.7% (55/132) | 47.7% (63/132) | |
| Constant | 9.1% (12/132) | 2.3% (3/132) | 4.5% (6/132) | |
| Trend between T0 and T2 | ||||
| Increase | 77.3% (102/132) | 55.3% (73/132) | 56.8% (75/132) | - |
| Decrease | 15.2% (20/132) | 40.9% (54/132) | 41.7% (55/132) | |
| Constant | 7.6% (10/132) | 3.8% (5/132) | 1.5% (2/132) |
Data are given as % (N). T0, baseline; T2, end of treatment; QFT-P, QuantiFERON-TB Gold Plus; Constant, no difference in IFN-y levels between T0 and T2, regardless of variations during treatment. Positivity was set at 0.75 IU/ml for QFT-P and at 0.22 IU/ml for HBHA based on ROC analyses.